Last quarter (Q1 2024), Oramed Pharm's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Oramed Pharm's net income was $13.34M. See Oramed Pharm’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Aug 21	Aug 20
Total Revenue	$ 1.34M	$ 1.34M	$ 2.70M	$ 904.00K	$ 2.70M	$ 2.71M
Cost of Revenue	-	-	-	-	-	$ 0.00
Gross Profit	$ 1.34M	$ 1.34M	$ 2.70M	-	-	$ 2.71M
Operating Expense	$ 5.36M	$ 17.11M	$ 43.30M	$ 13.23M	$ 26.93M	$ 14.47M
Operating Income	$ -4.02M	$ -15.77M	$ -40.60M	$ -12.33M	$ -24.22M	$ -11.76M
Net Non Operating Interest Income Expense	$ -2.04M	$ -2.04M	$ 3.47M	$ 71.00K	$ 341.00K	$ 684.00K
Other Income Expense	$ -22.89M	$ -22.89M	$ -3.75M	-	$ 893.00K	$ -438.00K
Pretax Income	$ 16.84M	$ 5.09M	$ -37.66M	$ -12.26M	$ -22.99M	$ -11.51M
Tax Provision	-	-	$ 100.00K	-	-	$ 0.00
Earnings From Equity Interest Net Of Tax	$ 824.00K	$ 824.00K	-	-	-	-
Net Income Common Stockholders	$ 17.27M	$ 5.53M	$ -36.56M	$ -11.67M	$ -22.24M	$ -11.51M
Basic EPS	$ 0.52	$ 0.14	$ 0.94	$ -0.31	$ -0.78	$ -0.56
Diluted EPS	$ 0.50	$ 0.14	$ 0.94	$ -0.31	$ -0.78	$ -0.56
Basic Average Shares	$ 161.26M	$ 40.32M	$ 39.00M	$ 37.11M	$ 28.47M	$ 20.53M
Diluted Average Shares	$ 162.27M	$ 40.57M	$ 39.00M	$ 37.11M	$ 28.47M	$ 20.53M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 5.36M	$ 17.11M	$ 43.30M	$ 13.23M	$ 26.93M	$ 14.47M
Net Income From Continuing And Discontinued Operation	$ 5.31M	$ 5.53M	$ -36.56M	$ -11.67M	$ -22.24M	$ -11.51M
Normalized Income	$ 12.04M	$ 7.93M	-	$ -11.67M	$ -23.13M	$ -11.07M
Interest Expense	-	-	-	$ 87.00K	-	-
EBIT	$ 18.87M	$ 7.13M	$ -37.66M	$ -12.17M	$ -24.22M	$ -11.76M
EBITDA	$ 21.47M	$ 7.32M	$ -37.61M	$ -12.15M	$ -24.15M	$ -11.75M

Currency in USD

Oramed Pharm Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing